Wockhardt Limited has announced its audited financial results for the quarter and financial year ended March 31, 2026. The company achieved a significant turnaround, reporting an annual standalone net profit of ₹317 crore, a robust improvement compared to the net loss of ₹12 crore in the previous year. The Board has also approved an enabling proposal to raise funds through various instruments, subject to shareholder approval at the upcoming Annual General Meeting.
Financial Highlights
Wockhardt Limited delivered a strong performance for the financial year ending March 31, 2026. The standalone revenue from operations climbed to ₹1,739 crore, up from ₹1,402 crore in the previous year. For the final quarter (Q4), the standalone net profit stood at ₹167 crore, significantly outperforming the ₹40 crore profit recorded in the same period last year. On a consolidated basis, the company reported annual revenue of ₹3,373 crore and a net profit of ₹199 crore.
Strategic Business Updates
The company successfully concluded a settlement regarding its legal dispute with Dr. Reddy’s Laboratories concerning a 2020 Business Transfer Agreement. This resolution, combined with the successful execution of specific benchmarks, resulted in a net gain of ₹35 crore recognized under ‘Exceptional Items’ in the March 2026 quarter.
Furthermore, the group has moved to exit its US generic pharmaceutical business, completing the deconsolidation of its US subsidiaries as of July 11, 2025. This strategic realignment is part of the company’s efforts to focus on core operations and improve its long-term financial stability.
Future Capital Raising
Reflecting its commitment to future growth, the Board has approved an enabling proposal to raise funds via the issuance of equity shares, convertible securities, or non-convertible securities. This may be executed through various channels including Qualified Institutions Placements (QIP) or preferential allotments, ensuring the company maintains the flexibility to capitalize on future opportunities pending shareholder consent.
Source: BSE
